Businesses in the industry are always concentrating on tactics like joint ventures and the creation and launch of new goods. These tactics will support the businesses in raising their revenue, which will fuel the expansion of the market.
The development of new goods with enhanced safety and convenient features is anticipated to support the expansion of the pharmaceutical sector. Better dosage characteristics also enhance the possibilities for illness management in homecare settings and support the outcomes of pharmacological treatment.
Increased product development and launch partnerships between industry participants and pharmaceutical companies will also contribute to the market’s growth. To develop and market Cambridge Healthcare Innovations Limited’s (CHI) αeolus Dry Powder Inhaler (DPI) platform technology, for example, KINDEVA DRUG DELIVERY and CHI joined forces in April 2021.
Patients are favoring modern drug delivery systems more and more because they can deliver drugs more precisely and selectively to a target region. These systems also reduce fluctuation in systemic drug concentrations. Patients are now more likely to use self-administered devices as a result of these features.
Additionally, since medical gadgets have become more digital, patients are now more aware of cutting-edge products. The usage of these devices will rise as a result of the digitalization of these medicines, which offers several benefits such regulated dosage, needle-free injection, and increased self-administration flexibility.
Research Methodology:
After secondary research provided a fundamental understanding of the worldwide Point of Care Diagnostics Market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering Point of Care Diagnostics Market details, as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered.
Electronic Drug Delivery Systems Market based on Type:
- Electronic Wearable Infusion Pumps
- Electronic Autoinjectors
- Electronic Injection Pens
- Electronic Inhalers
Electronic Drug Delivery Systems Market based on Indication:
- Diabetes
- Multiple Sclerosis
- Cardiovascular Disease
- Asthma & COPD
- Other Indications
Electronic Drug Delivery Systems Market based on Geography:
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific (RoAPAC)
- Latin America (LATAM)
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa (MEA)
- UAE
- Turkey
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
The market is divided into four categories based on type: electronic inhalers, electronic injection pens, electronic autoinjectors, and wearable infusion pumps. In 2019, the market share projected to be greatest in the electronic wearable infusion pumps segment. The market is expanding because commercial infusion pumps are more widely available for treating diabetes than other kinds of electronic medication delivery devices.
In 2018, the diabetes market category held the biggest market share. This is mostly because, compared to other therapeutic areas, leading market participants have a greater supply of electronic drug delivery devices, such as insulin pumps and injectable pens, and diabetes is a disease that is more common worldwide. For example, the number of Americans with diabetes was approximately 30.2 million in 2017, and by 2045, it is predicted to rise to 35.6 million.
In 2018, the market was dominated by North America. Over the course of the projected period, the region of North America is anticipated to see the greatest CAGR. Some of the main reasons propelling the expansion of this geographical segment are the increasing prevalence of target diseases, the advantageous reimbursement scenario, approvals, and launches of cutting-edge electronic drug delivery systems in the area. For example, the Minimed 670G system, an electronic infusion pump, was introduced in the United States by Medtronic PLC (Ireland) in June 2017.
The Merck Group (Germany), Insulet Corporation (US), Bayer AG (Germany), Medtronic plc (Ireland), Novo Nordisk (Denmark), United Therapeutics Corporation (US), AstraZeneca (UK), Tandem Diabetes Care (US), and Amgen (US) are notable participants in the electronic medication delivery system market.
In 2018, Merck Group held a 23.0% market share, leading the electronic drug delivery systems industry. The company creates, produces, and markets vaccines, health goods, biologic therapies, and prescription drugs. In order to hold onto its dominant market position, the corporation prioritizes organic growth techniques including expansions. For example, the Merck group established a new OLED (organic light-emitting diode) technology center in China in February 2018. The goal was to create and improve cutting-edge technologies for Asia Pacific’s key markets.
- This report illustrates the most vital attributes of the Electronic Drug Delivery Systems Market, which are driving and providing opportunities.
- This research gives an in-depth analysis of the Electronic Drug Delivery Systems Market growth on the basis of several segments in the market.
- This report presents the predictions of the past and present trends of the Electronic Drug Delivery Systems Market.
- This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Electronic Drug Delivery Systems Market.
Methodology
Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:
- Data Collation (Primary & Secondary)
- In-house Estimation (Based on proprietary data bases and Models)
- Market Triangulation
- Forecasting
List of Tables
TABLE 1. ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 2. ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE FOR ELECTRONIC WEARABLE INFUSION PUMPS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 3. ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE FOR ELECTRONIC AUTOINJECTORS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE FOR ELECTRONIC INJECTION PENS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 5. ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE FOR ELECTRONIC INHALERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 6. ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 7. ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE FOR DIABETES, 2021-2030 (USD BILLION)
TABLE 8. ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE FOR MULTIPLE SCLEROSIS, 2021-2030 (USD BILLION)
TABLE 9. ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE FOR CARDIOVASCULAR DISEASE, 2021-2030 (USD BILLION)
TABLE 10. ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE FOR ASTHMA & COPD, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 11. ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE FOR OTHER INDICATIONS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 12. NORTH AMERICA ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 13. NORTH AMERICA ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 14. NORTH AMERICA ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 15. U.S ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 16. U.S ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 17. U.S ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 18. CANADA ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 19. CANADA ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 20. MEXICO ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 21. MEXICO ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 22. EUROPE ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 23. EUROPE ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 24. EUROPE ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 25. GERMANY ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 26. GERMANY ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 27. U.K ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 28. U.K ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 29. FRANCE ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 30. FRANCE ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 31. ITALY ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 32. ITALY ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 33. SPAIN ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 34. SPAIN ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 35. ROE ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 36. ROE ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 37. ASIA PACIFIC ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 38. ASIA PACIFIC ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 39. ASIA PACIFIC ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 40. CHINA ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 41. CHINA ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 42. INDIA ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 43. INDIA ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 44. JAPAN ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 45. JAPAN ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 46. REST OF APAC ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 47. REST OF APAC ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 48. LATIN AMERICA ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 49. LATIN AMERICA ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 50. BRAZIL ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 51. BRAZIL ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 52. ARGENTINA ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 53. ARGENTINA ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 54. MIDDLE EAST AND AFRICA ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 55. MIDDLE EAST AND AFRICA ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 56. SAUDI ARABIA ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 57. SAUDI ARABIA ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 58. UAE ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 59. UAE ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 60. REST OF MIDDLE EAST AND AFRICA ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 61. REST OF MIDDLE EAST AND AFRICA ELECTRONIC DRUG DELIVERY SYSTEMS MARKET VALUE, BY INDICATION, 2021-2030 (USD BILLION)
TABLE 62. MEDTRONIC PLC (IRELAND): FINANCIALS
TABLE 63. MEDTRONIC PLC (IRELAND): PRODUCTS & SERVICES
TABLE 64. MEDTRONIC PLC (IRELAND): RECENT DEVELOPMENTS
TABLE 65. NOVO NORDISK (DENMARK): FINANCIALS
TABLE 66. NOVO NORDISK (DENMARK): PRODUCTS & SERVICES
TABLE 67. NOVO NORDISK (DENMARK): RECENT DEVELOPMENTS
TABLE 68. INSULET CORPORATION (US): FINANCIALS
TABLE 69. INSULET CORPORATION (US): PRODUCTS & SERVICES
TABLE 70. INSULET CORPORATION (US): RECENT DEVELOPMENTS
TABLE 71. BAYER AG (GERMANY): FINANCIALS
TABLE 72. BAYER AG (GERMANY): PRODUCTS & SERVICES
TABLE 73. BAYER AG (GERMANY): RECENT DEVELOPMENTS
TABLE 74. UNITED THERAPEUTICS CORPORATION (US): FINANCIALS
TABLE 75. UNITED THERAPEUTICS CORPORATION (US): PRODUCTS & SERVICES
TABLE 76. UNITED THERAPEUTICS CORPORATION (US): RECENT DEVELOPMENTS
TABLE 77. ASTRAZENECA (UK): FINANCIALS
TABLE 78. ASTRAZENECA (UK): PRODUCTS & SERVICES
TABLE 79. ASTRAZENECA (UK): RECENT DEVELOPMENTS
TABLE 80. TANDEM DIABETES CARE (US): FINANCIALS
TABLE 81. TANDEM DIABETES CARE (US): PRODUCTS & SERVICES
TABLE 82. TANDEM DIABETES CARE (US): DEVELOPMENTS
TABLE 83. MERCK GROUP (GERMANY): FINANCIALS
TABLE 84. MERCK GROUP (GERMANY): PRODUCTS & SERVICES
TABLE 85. MERCK GROUP (GERMANY): RECENT DEVELOPMENTS
TABLE 86. AMGEN (US): FINANCIALS
TABLE 87. AMGEN (US): PRODUCTS & SERVICES
TABLE 88. AMGEN (US): RECENT DEVELOPMENTS
TABLE 89. COMPANION MEDICAL (US): FINANCIALS
TABLE 90. COMPANION MEDICAL (US): PRODUCTS & SERVICES
TABLE 91. COMPANION MEDICAL (US): RECENT DEVELOPMENTS
